Kiran Prakash Patil
Sunila A. Patil
- Research Scholar Department of Quality Assurance, P.S.G.V.P. Mandal’s College of Pharmacy Maharashtra India
- Assistance Professor Department of Pharmaceutical Chemistry, P.S.G.V.P. Mandal’s College of Pharmacy Maharashtra India
Abstract
Luliconazole, an antifungal agent of the imidazole class, possesses a distinctive structure where the imidazole component is fused with the ketene dithioacetate configuration. It exists in its R-enantiomer form, which exhibits greater antifungal efficacy compared to lanoconazole, a compound comprising a racemic blend. Strong action is shown by luliconazole against filamentous fungi, such as dermatophytes. The pharmacokinetic characteristics of dermatophytes, such as Trichophyton rubrum and Microsporum gypseum, help explain why they are useful in treating dermatophytic infections. Similar to terbinafine, luliconazole exhibits potent fungicidal activity against Trichophyton spp. Despite being an azole. Luliconazole, which comes in two forms-a 1% topical cream and a 10% solution-has demonstrated notable effectiveness in the treatment of diseases like onychomycosis, tinea pedis, and tinea cruris. luliconazole is more effective than other antifungals such as clotrimazole, its distinct molecular structure also improves penetration into the nail plate. Luliconazole’s effective antifungal pastime in vitro and its pharmacokinetic Characteristics inside the pores and skin. Even when carried out for a bit period of time-one week for tinea Corporis, tinea cruris and two weeks for tinea pedis-luliconazole 1% cream once daily is effective. Japan permitted the usage of 1% luliconazole cream in 2005 to treat tinea infections. The US Food And Drug Administration has simply authorized it for the remedy of tinea corporis, tinea cruris And tinea pedis. Topical luliconazole has a very good protection profile. This evaluation article aims to Synthesize modern-day know-how on luliconazole, specializing in its chemical properties, mechanism of action, medical efficacy and application in treating fungal infections.
Keywords: Luliconazole, Fungal infections, Dermatophytes, Antifungal agent, Pharmacokinetics.
[This article belongs to Trends in Drug Delivery(tdd)]
Browse Figures
References
1. Amber Vyas, Vishal Jain. Luliconazole promising drug for Dermatophytes: A Review. International Journal of Technology. 2023; 13(2):79-4 doi: 10.52711/2231-3915.2023.00010.
2. Alam, M. S., Misra, A., & Mishra, P. K. (2020). Efficacy of topical Luliconazole in management of tinea corporis and tinea cruris infections. International Journal of Health and Clinical Research, 3(8), 89–92.
3. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J 2016;7:77-86.
4. Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. Jul 2014;57(7):389-93. doi:10.1111/myc.12168.
5. Shokri A, Abastabar M, Keighobadi M, et al. Promising antileishmanial activity of novel imidazole antifungal drug luliconazole against Leishmania major: In vitro and in silico studies. J Glob Antimicrob Resist. Sep 2018;14:260-265. doi:10.1016/j.jgar.2018.05.007.
6. Dakhale GN, Gupta AV, Mukhi JI, Kalikar MVJPiCR. Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses: A prospective, randomized, open-label study. 2021;12(4):223-8.
7. Dias MF, Bernardes-Filho F, Quaresma-Santos MV, Amorim AG, Schechtman RC, Azulay DR. Treatment of superficial mycoses: review. Part II. An Bras Dermatol. 2013;88:937–944.
8. Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid. 2014 Sep 24;9:113-24. doi: 10.2147/CE.S49629.
9. Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NL, Correr CJ. Efficacy of topical antifungals in the treatment of dermatophytosis: A mixed‑treatment comparison meta‑analysis involving 14 treatments. JAMA Dermatol 2013;149:341‑9.
10. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007;(3):CD001434.
11. Elewski BE, Vlahovic TC. Econazole nitrate foam 1% for the treatment of tinea pedis: Results from two double‑blind, vehicle‑controlled, phase 3 clinical trials. J Drugs Dermatol 2014;13:803‑8.
12. Bseiso EA, Nasr M, Sammour O, Abd El Gawad NA. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol 2015;81:457‑63.
Trends in Drug Delivery
| Volume | 11 |
| Issue | 02 |
| Received | April 15, 2024 |
| Accepted | May 4, 2024 |
| Published | June 14, 2024 |